India Seen As Concentrated Market For Vaccine Production
This article was originally published in PharmAsia News
Executive Summary
India's vaccine market is being looked upon by the pharmaceutical industry as more attractive as companies begin to look to the nation as a production source. Novartis of Switzerland already has a major investment in producing vaccines in India, including a facility dedicated to human rabies vaccines. Market analysts estimate vaccines as a market in India worth $665 million in the past year, growing at the rate of 20 percent a year. India counts six essential vaccines as part of its national immunization program. (Click here for more